Orforglipron for Obesity

(ATTAIN-NOW Trial)

This trial tests the effectiveness and safety of a new treatment called orforglipron for individuals who are overweight. Researchers aim to determine if this treatment can reduce the risk of obesity-related health issues, such as type 2 diabetes and high blood pressure. The study includes three groups: one taking orforglipron, one starting with orforglipron and switching to a placebo (inactive substance), and one starting with a placebo and switching to orforglipron. Participants should have a waist-to-height ratio of at least 0.5, have unsuccessfully attempted weight loss through diet and exercise, and have a BMI between 25 and 29.9, along with one obesity-related complication like prediabetes or prehypertension. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants a chance to contribute to potentially groundbreaking treatment advancements.

Research has shown that orforglipron, a pill acting as a GLP-1 receptor agonist, demonstrates promising safety results in humans. Earlier studies found it to be as safe as, or even safer than, insulin. However, some side effects have been reported. About 90% of people taking the drug experienced side effects, mostly similar to those seen with other drugs in this group, typically including stomach issues like nausea or diarrhea.

Orforglipron is unique because it's an oral medication targeting obesity, which could offer a more convenient alternative to current injectable treatments like semaglutide. Unlike other obesity treatments that focus on appetite suppression or fat absorption, Orforglipron works by mimicking a hormone that helps control blood sugar and appetite, potentially leading to significant weight loss. Researchers are excited because this new delivery method could make it easier for patients to manage their condition, improving adherence and outcomes.

Research has shown that orforglipron can help people with obesity lose weight. In one study, participants taking a high dose lost about 12.4% of their body weight over 72 weeks, while those on a placebo lost only 2.1%. Another study found that a 6-milligram dose led to an average weight loss of 16 pounds. Orforglipron also helped control blood sugar levels, potentially preventing type 2 diabetes. Some participants experienced side effects like nausea, which is common with this type of treatment. Overall, evidence suggests that orforglipron can aid in weight loss and reduce obesity-related health risks.⁶⁷⁸⁹¹⁰